Bishwas Shrestha

机构：Fate Therapeutics (United States) · ORCID：0000-0002-6159-7686

发表论文 52 篇 · 总被引 1127 次 · h-index 17

代表论文

• CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function (2020 · Cancer Immunology Research · 被引 82)
• Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease (2020 · Journal of Clinical Investigation · 被引 63)
• Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia (2023 · Molecular Therapy — Oncolytics · 被引 34)
• Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells (2019 · Journal of Immunotherapy · 被引 28)
• Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy (2025 · Cell stem cell · 被引 22)
• Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells (2022 · Journal of Immunotherapy · 被引 22)